United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $511.97, for a total value of $4,863,715.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $166,105,082.71. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
United Therapeutics Stock Performance
Shares of UTHR stock opened at $516.68 on Thursday. United Therapeutics Corporation has a 1 year low of $302.19 and a 1 year high of $609.35. The business’s fifty day moving average is $531.06 and its 200-day moving average is $538.56. The stock has a market cap of $22.16 billion, a PE ratio of 18.49, a price-to-earnings-growth ratio of 1.76 and a beta of 0.59.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the prior year, the firm posted $6.41 earnings per share. The company’s revenue was down 1.9% on a year-over-year basis. Equities research analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on United Therapeutics
Institutional Trading of United Therapeutics
Large investors have recently added to or reduced their stakes in the company. Toth Financial Advisory Corp lifted its holdings in shares of United Therapeutics by 2,400.0% in the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares in the last quarter. Torren Management LLC purchased a new position in shares of United Therapeutics during the fourth quarter valued at $26,000. Fiduciary Financial Advisors purchased a new position in shares of United Therapeutics during the second quarter valued at $30,000. Activest Wealth Management raised its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the period. Finally, Entrust Financial LLC purchased a new stake in United Therapeutics in the 4th quarter worth about $31,000. 94.08% of the stock is owned by institutional investors and hedge funds.
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
- Five stocks we like better than United Therapeutics
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
